The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Your search for esrd returned 12 results
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Sarilumab administered every 2 weeks is associated with similar improvements in physical function in adult patients with rheumatoid arthritis, compared with adalimumab.
A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.
Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and “appeared similar regardless of methotrexate dose” in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
Obese patients diagnosed with rheumatoid arthritis (RA) can improve disease control by losing weight, according to a study reported at the 2015 ACR/ARHP Annual Meeting.
Long-term etanercept is associated with modestly better treatment retention rates than adalimumab among patients with rheumatoid arthritis (RA), according to an analysis of data from the RHUMADATA® clinical registry and database presented at the 2015 ACR/ARHP Annual Meeting.